目的 探讨脑心通胶囊联合甲磺酸二氢麦角碱缓释片治疗脑梗死恢复期的临床疗效。方法 选择2022年1月—2022年12月江苏省苏北人民医院收治的84例脑梗死恢复期患者，随机分为对照组（42例）及治疗组（42例）。对照组患者口服甲磺酸二氢麦角碱缓释片，1片/次，2次/d。在对照组的基础上，治疗组口服脑心通胶囊，3粒/次，3次/d。两组患者用药治疗30 d。比较治疗前后两组患者临床疗效、症状缓解时间及美国研究院卒中评分量表（NIHSS），日常生活活动能力评分量表（ADL）和Fugl-Meyer评分量表（FMA）评分。结果 治疗后，治疗组总有效率为95.24%，明显高于对照组（80.95%，P＜0.05）。治疗后，治疗组症状缓解时间均明显早于对照组（P＜0.05）。治疗后，两组患者NIHSS评分明显降低，而ADL评分和FMA评分明显升高（P＜0.05），且治疗组ADL、FMA和NIHSS评分明显好于对照组（P＜0.05）。结论 甲磺酸二氢麦角碱缓释片与脑心通胶囊协同治疗，能有效缓解脑梗死患者症状，明显恢复脑神经缺损，提升日常活动能力。

Objective To explore the clinical effect of Naoxintong Capsules combined with Dihydroergotoxine Methanesulfonate Sustained Release Tablets in treatment of recovery period of cerebral infarction. Methods Patients (84 cases) with recovery period of cerebral infarction in Northern Jiangsu People’s Hospital from January 2022 to December 2022 were randomly divided into control (42 cases) and treatment (42 cases) group. Patients in the control group were po administered with Dihydroergotoxine Methanesulfonate Sustained Release Tablets, 1 tablet/time, twice daily. Patients in the treatment group were po administered with Naoxintong Capsules on the basis of the control group, 3 grains/time, three times daily. All patients were treated for 30 d. The clinical evaluations, symptom relief time, the scores of ADL, NIHSS and FMA in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group was 95.24%, which was significantly higher than 80.95% of the control group ( P < 0.05). After treatment, the time of symptom relief in the treatment group was significantly earlier than that in the control group (P < 0.05). After treatment, NIHSS score in two groups was significantly decreased, while ADL and FMA scores were significantly increased (P < 0.05), and the scores in the treatment group were significantly better than those in the control group (P < 0.05). Conclusion The combined treatment of Dihydroergotoxine Methanesulfonate Sustained Release Tablets and Naoxintong Capsules can effectively relieve the symptoms, obviously restore the brain nerve defect and improve the ability of daily activity.

R971

国家卫生健康委脑卒中防治工程委员会项目（GN-2018R0010）